Long-Term Effects of Semaglutide and Sitagliptin on Circulating IGFBP-1, IGFBP-3 and IGFBP-rp1: Results from a One-Year Study in Type 2 Diabetes
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262110404 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Eszter Dániel und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sitagliptin Phosphate, Insulin-Like Growth Factor Binding Protein 1, Glucagon-Like Peptides. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research, Development and Innovation Office, Hungarian Society for Endocrinology and Metabolism.
Themen: Diabetes mellitus
Abstract (Originalsprache)
The role of insulin-like growth factor-binding proteins (IGFBPs) in the regulation of carbohydrate metabolism and the development of complications is well established; however, the impact of the glucagon-like peptide-1 receptor agonist semaglutide on IGFBPs has not been previously investigated. We aimed to examine the effects of semaglutide and dipeptidyl peptidase-4 inhibitor sitagliptin therapy on serum levels of IGFBP-1, IGFBP-3, and IGFBP-rp1, and to analyze their associations with anthropometric variables and markers of carbohydrate and lipid metabolism. In this prospective study, we enrolled 34 patients with type 2 diabetes mellitus (T2DM) on metformin monotherapy and 31 age-, sex- and BMI-matched controls. Among the patients, 18 received semaglutide, and 16 were treated with sitagliptin. Anthropometric and laboratory assessments were performed at baseline, 26 and 52 weeks. IGFBP levels were measured using ELISA. Both semaglutide and sitagliptin treatment significantly increased IGFBP-1 levels. IGFBP-3 levels were significantly decreased following sitagliptin therapy. No significant change in IGFBP-rp1 levels was observed with either treatment. Based on multiple regression analysis, the best predictors of IGFBP-1 were insulin and hsCRP, while the best predictor of IGFBP-3 was LDL-C level. Our findings suggest that semaglutide and sitagliptin may exert favorable effects on the GH/IGF-1 axis, potentially contributing to their beneficial metabolic outcomes in patients with T2DM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary.
- Doctoral School of Health Sciences, University of Debrecen, H-4032 Debrecen, Hungary.
- Department of Clinical Basics, Faculty of Pharmacy, University of Debrecen, H-4032 Debrecen, Hungary.
- Department of Emergency Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary.
- Institute of Health Studies, Faculty of Health Sciences, University of Debrecen, H-4032 Debrecen, Hungary.
ORCID-Profile: Balázs Ratku, Mariann Harangi, Hajnalka Lőrincz
Förderung
- National Research, Development and Innovation Office
- Hungarian Society for Endocrinology and Metabolism
Zitieren
APA
Dániel, E., Sztanek, F., Csiha, S., Ratku, B., Somodi, S., Paragh, G., Harangi, M., & Lőrincz, H. (2025). Long-Term Effects of Semaglutide and Sitagliptin on Circulating IGFBP-1, IGFBP-3 and IGFBP-rp1: Results from a One-Year Study in Type 2 Diabetes. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262110404
Vancouver
Dániel E, Sztanek F, Csiha S, Ratku B, Somodi S, Paragh G, et al. Long-Term Effects of Semaglutide and Sitagliptin on Circulating IGFBP-1, IGFBP-3 and IGFBP-rp1: Results from a One-Year Study in Type 2 Diabetes. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262110404
BibTeX
@article{Dniel2025,
author = {Dániel, Eszter and Sztanek, Ferenc and Csiha, Sára and Ratku, Balázs and Somodi, Sándor and Paragh, György and Harangi, Mariann and Lőrincz, Hajnalka},
title = {Long-Term Effects of Semaglutide and Sitagliptin on Circulating IGFBP-1, IGFBP-3 and IGFBP-rp1: Results from a One-Year Study in Type 2 Diabetes},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262110404}
}
EUVIMED